Drug Shortage Report for MOUNJARO

Last updated on 2024-08-31 History
Report ID 210458
Drug Identification Number 02541084
Brand name MOUNJARO
Common or Proper name tirzepatide injection
Company Name ELI LILLY CANADA INC
Market Status MARKETED
Active Ingredient(s)
Strength(s) 10MG
Dosage form(s) SOLUTION
Route of administration SUBCUTANEOUS
Packaging size 3 mL single-dose vial
ATC code A10BX
ATC description
Reason for shortage Other (Please describe in comments)
Anticipated start date 2023-12-12
Actual start date 2023-12-04
Estimated end date 2024-09-03
Actual end date 2024-08-30
Shortage status Resolved
Updated date 2024-08-31
Company comments Contact our Lilly Customer Response Centre at 1-888-545-5972 (Monday-Friday, 9 a.m. to 5 p.m. Eastern Time, excluding holidays) for more information. We are committed to supplying MOUNJARO® for people with type 2 diabetes. Lilly continues to invest and add manufacturing and supply capacity around the world. We are working closely with government entities and other stakeholders to ensure we are doing everything possible to meet the needs of patients with type 2 diabetes.
Health Canada comments
Tier 3 Status No
Contact Address EXCHANGE TOWER, 130 KING STREET WEST
TORONTO, ONTARIO
CANADA M5X 1B1
Company contact information Lilly Canada’s Customer Response Centre 1-888-545-5972.

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v17 2024-08-31 English Compare
v16 2024-08-30 French Compare
v15 2024-08-30 English Compare
v14 2024-08-30 English Compare
v13 2024-08-30 English Compare
v12 2024-05-28 French Compare
v11 2024-05-28 English Compare
v10 2024-05-09 French Compare
v9 2024-05-09 English Compare
v8 2024-02-22 French Compare
v7 2024-02-22 English Compare
v6 2024-02-02 French Compare
v5 2024-02-02 English Compare
v4 2023-12-05 French Compare
v3 2023-12-05 English Compare
v2 2023-11-17 French Compare
v1 2023-11-17 English Compare

Showing 1 to 17 of 17